Pharma Starts its Psychedelic Journey

Steffanie Wilson at The Emmes Company affirms that both public and medical opinion is changing quickly and substances that were once regarded as ‘party drugs’, psychedelics such as MDMA, LSD and psilocybin (the active ingredient found in magic mushrooms) are now being studied increasingly as potential treatments for a number of different neuropsychiatric disorders including PTSD, intractable depression and alcohol addiction.